Treatment of Acute Myeloid Leukemia Carrying Inv(2)(p23q13)/Ranbp2-Alk With Crizotinib and the Mechanism of Resistance to the Drug

Tenri Medical Bulletin
doi 10.12936/tenrikiyo.18-012
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Tenri Foundation, Tenri Institute of Medical Research

Related search

Drug Repurposing for the Treatment of Acute Myeloid Leukemia

Frontiers in Medicine
Medicine
2017English

Slow Relapse in Acute Myeloid Leukemia With Inv(16) or T(16;16)

Haematologica
Hematology
2009English

The Clinical Relevance of Cellular Drug Resistance Testing in Childhood Acute Myeloid Leukemia (AML)

Pediatric Research
Child HealthPediatricsPerinatology
1999English

Expression of P‑gp in Acute Myeloid Leukemia and the Reversal Function of As2O3 on Drug Resistance

Oncology Letters
Cancer ResearchOncology
2014English

FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2011English

Inhibition of EZH2 Degradation as a Novel Approach to Overcome Drug Resistance in Acute Myeloid Leukemia

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2017English

Prediction of ALK Mutations Mediating ALK-TKIs Resistance and Drug Re-Purposing to Overcome the Resistance

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

Treatment Patterns and Outcomes of Octogenarian Patients With Acute Myeloid Leukemia

American Journal of Hematology
Hematology
2019English

LncRNA ZEB2-AS1 Regulates the Drug Resistance of Acute Myeloid Leukemia via the miR-142-3p/INPP4B Axis

RSC Advances
ChemistryChemical Engineering
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy